Acutus Medical Announces Full Market Release of next generation software platform AcQMap 8.5

Software improvements further leverage the system’s unique ultrasound capabilities for non-contact anatomy reconstruction

CARLSBAD, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the full commercial release of AcQMap 8.5. This next generation software platform introduces new algorithms and features to further improve the accuracy and workflow of non-contact ultrasound-based anatomical reconstruction.

“AcQMap 8.5 represents an important step forward in our technology roadmap with a specific focus on improving procedure workflow and physician experience,” said Derrick Chou, Senior Vice President & Chief Technology Officer of Acutus Medical. “This release enables physicians to further leverage AcQMap’s differentiated non-contact ultrasound capabilities for higher anatomical accuracy while providing a workflow that fits with existing clinical practice. The full market release of AcQMap 8.5 is an important driver of our growth plans in 2023 and thereafter.”

The AcQMap 8.5 software release enhances Acutus’ unique ultrasound capabilities by providing more fidelity and definition around key atrial structures like the pulmonary veins and left and right atrial appendage as well as highlighting open structures on the surface (e.g., mitral valve), making them easy to confidently locate, visualize, and incorporate into an individualized treatment strategy. Additionally, new workflow tools, like on-the-fly editing, have been added to further increase the efficiency and accuracy of the ultrasound-based anatomical reconstruction process. The updated algorithms in AcQMap 8.5 also improve catheter localization and visualization with a more accurate anatomical reference. Ultimately, AcQMap 8.5 provides a higher fidelity of anatomical accuracy and workflow efficiencies which allow for broader utilization of the AcQMap technology.

Acutus’ single beat, whole chamber, non-contact electro-anatomical mapping uniquely provides a holistic view of each patient’s disease enabling guidance of an individualized and optimized treatment approach. “AcQMap’s non-contact, ultrasound technology enables me to create a high-fidelity anatomy faster than most other conventional systems. This new software has been instrumental in getting better definition and catheter localization, particularly around structures which are difficult to achieve with conventional mapping technology. This accurate anatomy, combined with unique and powerful diagnostic and visualization algorithms, enables me to take a personalized approach when treating my patients with difficult-to-manage arrhythmias,” said Douglas Gibson, MD, Director of Cardiac Electrophysiology at Scripps Clinic

To learn more about Acutus Medical’s complete portfolio of diagnostic, access and therapy products, please visit https://acutusmedical.com.

About Acutus Medical
Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Follow Acutus Medical on: TwitterLinkedInYouTube and Facebook.

Investor Contact
Caroline Corner 
415-202-5678
caroline.corner@westwicke.com

Media Contact 
Peter Neems
442-232-6094
peter.neems@acutus.com

About The Wall Street Analyzer 1245 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.

Be the first to comment

Leave a Reply